What is cholecystokinin?

A gut hormone released when fat and protein reach the small intestine. It stimulates bile secretion and makes the gallbladder contract.

How do GLP-1 drugs affect it?

Rehfeld 2018 reported that GLP-1 suppresses CCK secretion, and framed this as the clue to the mechanism behind gallbladder adverse events.

Isn't it just the weight loss?

Rapid weight loss is an independent risk factor, but the CCK finding gives a second direct pathway. The two act together and are hard to separate.

GLP-1 & Incretin Science

The Hormone That Empties the Gallbladder, Suppressed

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

Cholecystokinin stimulates bile secretion and drives gallbladder contraction. Rehfeld and colleagues reported that GLP-1 suppresses cholecystokinin secretion, and framed this explicitly as the clue to the mechanism behind gallbladder adverse events with GLP-1-derived drugs.

Key facts

Key mediator: Cholecystokinin (CCK)
CCK's normal role: Bile secretion, gallbladder emptying
Effect of GLP-1: Suppresses CCK secretion
Consequence: Reduced gallbladder emptying
Mechanism paper: Rehfeld 2018 (PMID 30449207)
Related work: Gether 2019, JCEM (PMID 30137354)

What cholecystokinin does

CCK is released from the upper small intestine when fat and protein arrive. It stimulates pancreatic enzyme secretion and causes the gallbladder to contract, expelling stored bile into the intestine where it emulsifies fat. Its name is literal — cholecysto, gallbladder; kinin, to move.

Why gallbladder emptying matters

Bile stored in a gallbladder that empties infrequently becomes concentrated, and concentrated bile is closer to the point at which its cholesterol content precipitates. Stasis is the classical precondition for gallstone formation, which is why any condition reducing gallbladder emptying — prolonged fasting, intravenous feeding — raises stone risk.

Research material referenced

Retatrutide 10mg — third-party HPLC tested

View — £59.99

What Rehfeld and colleagues reported

That GLP-1 suppresses CCK secretion. Their 2018 paper in the Scandinavian Journal of Gastroenterology carries the inference in its own title, describing the finding as the clue to the mechanism of the adverse gallbladder events of GLP-1-derived drugs. The reasoning is stated in the abstract: since CCK regulates gallbladder motility and emptying, suppressing it would reduce them.

Why this is a stronger explanation than weight loss alone

Rapid weight loss is itself a recognised gallstone risk factor, so the effect could plausibly have been attributed entirely to the weight reduction these drugs produce. Identifying a specific mediator that these drugs suppress gives a second, direct pathway — and it predicts an effect that would not be explained by the magnitude of weight loss alone.

Why the two pathways are hard to separate

They act in the same participants in the same direction. Someone receiving a GLP-1 receptor agonist is simultaneously losing weight rapidly and experiencing reduced CCK-driven gallbladder emptying. This is the same attribution problem that runs through the cardiovascular and renal literature for this class — collinear exposures cannot be disentangled after the fact.

What this concerns

Licensed medicines studied in registered trials. Nothing supplied on this site is a GLP-1 receptor agonist, affects cholecystokinin, or has any bearing on gallbladder function in any person.

Extended research context

The GLP-1 & Incretin Science deep dive

Deep dive: the two routes to a bigger effect

Every compound trying to beat GLP-1 alone has taken one of two routes. The first adds more receptors from the same hormone family — GIP in tirzepatide, GIP and glucagon in retatrutide. The second adds a non-incretin satiety hormone, which in practice means amylin: CagriSema combines cagrilintide with semaglutide, and amycretin engages both receptors from one molecule. Both routes work, because they recruit signalling pathways that do not fully overlap. Neither has escaped the constraint that binds all of them, which is that gastrointestinal tolerability worsens as effect size grows.

Deep dive: why a percentage is not a result

The most-quoted numbers in this field are the least comparable. REDEFINE 1 reported 22.7% and 20.4% for the same compound in the same trial — the first among participants who adhered to treatment, the second across everyone randomised. TRIUMPH-1 reported 28.3% in an uncomplicated obesity population while TRIUMPH-3 reported up to 22.6% in adults with established cardiovascular disease, using the same compound. Before any two figures can be compared they have to match on estimand, population, duration, comparator and whether the number is placebo-adjusted. Most published comparisons match on none of them.

Deep dive: what happens after the trial stops

Every headline figure describes weight while treatment continues. The STEP-1 extension found that a year after semaglutide was stopped, participants had given back roughly two-thirds of what they lost, moving from 17.3% mean reduction to a net 5.6% — though average weight remained below baseline and nearly half stayed at least 5% down. Meta-analysis puts regain at around 0.8 kg per month. This is why maintenance studies such as TRIUMPH-6 matter more to the field's future than another two points of peak reduction.

Research applications

▸Comparing incretin and amylin compounds on a like-for-like basis
▸Interpreting estimands, thresholds and placebo-adjusted figures in trial reports
▸Tracking the obesity pipeline across sponsors and jurisdictions
▸Understanding receptor pharmacology behind GLP-1, GIP, glucagon and amylin
▸Distinguishing licensed medicines from investigational compounds

Handling checklist

✓Identify which estimand a quoted percentage comes from before citing it
✓Check the trial population and baseline BMI against the comparison you are making
✓Confirm the duration and whether the reduction curve had plateaued
✓Read discontinuation rates alongside efficacy figures
✓Verify every NCT identifier against ClinicalTrials.gov rather than secondary reporting

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Comparing headline percentages across different trials

Fix: Population, duration, estimand and comparator all differ; the numbers are not interchangeable.

✗ Quoting the larger of two figures from the same trial

Fix: Name the estimand. Efficacy and treatment-policy answer different questions.

✗ Treating peak reduction as a durable outcome

Fix: Substantial regain follows cessation across the class; peak figures describe a maintained state.

✗ Assuming an oral route means a weaker mechanism

Fix: Route and receptor count are independent. Orforglipron is weaker because it hits one receptor, not because it is a tablet.

✗ Reading investigational compounds as available treatments

Fix: Most of this pipeline holds no authorisation anywhere; mazdutide is approved only in China.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

What is cholecystokinin?: A gut hormone released when fat and protein reach the small intestine. It stimulates bile secretion and makes the gallbladder contract.
How do GLP-1 drugs affect it?: Rehfeld 2018 reported that GLP-1 suppresses CCK secretion, and framed this as the clue to the mechanism behind gallbladder adverse events.
Isn't it just the weight loss?: Rapid weight loss is an independent risk factor, but the CCK finding gives a second direct pathway. The two act together and are hard to separate.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More GLP-1 & Incretin Science articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum